Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Finished Goods: 2022-2024

Historic Finished Goods for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Dec 2024 value amounting to $9.6 million.

  • Arcutis Biotherapeutics' Finished Goods rose 42.14% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 42.14%. This contributed to the annual value of $9.6 million for FY2024, which is 257.51% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Finished Goods stood at $9.6 million for FY2024, which was up 257.51% from $2.7 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year Finished Goods high stood at $9.6 million for FY2024, and its period low was $1.5 million during FY2022.
  • For the 3-year period, Arcutis Biotherapeutics' Finished Goods averaged around $4.6 million, with its median value being $2.7 million (2023).
  • Data for Arcutis Biotherapeutics' Finished Goods shows a peak YoY soared of 257.51% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Arcutis Biotherapeutics' Finished Goods stood at $1.5 million in 2022, then spiked by 84.73% to $2.7 million in 2023, then spiked by 257.51% to $9.6 million in 2024.